KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells
London CA, Gardner HL, Rippy S, Post G, La Perle K, Crew L, Lopresti-Morrow L, Garton AJ, McMahon G, LaVallee TM, Gedrich R. KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells. Clinical Cancer Research 2017, 23: 2565-2574. PMID: 27815356, PMCID: PMC5418113, DOI: 10.1158/1078-0432.ccr-16-2152.Peer-Reviewed Original ResearchConceptsMast cell tumorsSpontaneous mast cell tumoursMast cell numbersMast cell degranulationCutaneous mast cell numberKIT phosphorylationCell degranulationOpen-label clinical studyBiochemical adverse eventsAcceptable safety profileMetastatic lymph nodesPharmacokinetics/pharmacodynamics profileFuture clinical evaluationClin Cancer ResCell numberDose-dependent mannerObjective responseAdverse eventsLymph nodesMCT patientsClinical effectsClinical toxicityClinical benefitHuman clinical applicationsSafety profileRetrospective evaluation of toceranib phosphate (Palladia) use in cats with mast cell neoplasia
Berger E, Johannes C, Post G, Rothchild G, Shiu K, Wetzel S, Fox L. Retrospective evaluation of toceranib phosphate (Palladia) use in cats with mast cell neoplasia. Journal Of Feline Medicine And Surgery 2017, 20: 95-102. PMID: 29172873, PMCID: PMC11129263, DOI: 10.1177/1098612x17695898.Peer-Reviewed Original ResearchConceptsMast cell neoplasiaCell neoplasiaAdverse eventsClinical benefitUse of toceranibDuration of therapyPossible clinical benefitFurther prospective studiesMajority of catsVeterinary Internal MedicineHematologic eventsToceranib treatmentGastrointestinal involvementMedian doseMedian durationDose adjustmentTreatment breaksProspective studyConcurrent treatmentAmerican CollegeRetrospective evaluationAnatomic classificationFeline patientsGastrointestinal casesToceranib